Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07767487
PHASE1

A Study of LY4226695 in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.

Official title: A Single-ascending and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4226695 in Healthy Participants

Key Details

Gender

All

Age Range

22 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

148

Start Date

2026-08

Completion Date

2027-07

Last Updated

2026-08-17

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4226695

Administered SC

DRUG

LY4226695

Administered IV

DRUG

Placebo

Administered SC

Locations (2)

CenExel ACT

Anaheim, California, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore